The Europeanization of regulatory policy in the EU pharmaceutical sector

Health Governance in Europe: Issues, Challenges, and Theories

Volumn , Issue , 2005, Pages 49-80

  Permanand, Govin ^a   Mossialos, Elias ^a  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 29344443199     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.4324/9780203015582     Document Type: Chapter

References (52)

1. Abraham , J. and Lewis , G. (2000) Regulating Medicines in Europe: Competition, Expertise and Public Health, London: Routledge.
2. Albedo (1991) 'Transparency Directive II: Sequel or Remake?', Pharmaceutical Technology Europe September: 12-20.
3. Albedo (1995) 'At Last, a Real European Milestone', Pharmaceutical Technology Europe December: 8-11.
4. Armstrong , K. and Bulmer , S. (1998) The Governance of the Single European Market, Manchester: Manchester University Press.
5. Bahner , B. (1993) 'Generic Drugs Threatened by New European Patent Law', Chemical Marketing Reporter 19 July: 3-5.
6. BEUC (1991) 'Longer Patent Protection Periods for Medicines: A Blank Cheque for the Pharmaceutical Industry?', BEUC press release, Brussels: Bureau Européen des Unions de Consommateurs.
7. BEUC (1994) BEUC's Opinion on the Outlines of an Industrial Policy for the Pharmaceutical Sector in the EC, Brussels: Bureau Européen des Unions de Consommateurs.
8. Brittan , L. (1992) 'Making a Reality of the Single Market: Pharmaceutical Pricing and the European Economic Community', paper presented to the Institute of Economic Affairs Conference on Pharmaceutical Policies in Europe , London, December 1992.
9. Burstall , M. (1992) 'The Transparency Directive: Is it Working?', Pharmacoeconomics 1 (supplement 1): 1-8.
10. Cameron McKenna (2000) Evaluation of the Operation of Community Procedures for the Authorisation of Medicinal Products, Report to the European Commission, European Commission: Directorate-General Enterprise (Pharmaceuticals and Cosmetics), Brussels: Commission of the European Communities.
11. CEC (1985) Completing the Internal Market: White Paper of the Commission to the European Council COM 83(310), Brussels: Commission of the European Communities.
12. CEC (1993) Background Report: The European Medicines Evaluation Agency, ISEC/B33/93.
13. CEC (1995) 'Inauguration of the European Agency for the Evaluation of Medicinal Products', press release DN: IP/95/64, 1995-01-26, Brussels: Commission of the European Communities.
14. CEC (2000) Pharmaceuticals in the European Union, Commission of the European Communities, Enterprise Directorate-General, Brussels: Commission of the European Communities.
15. Cecchini , P. with Catinat , M. and Jacquemin , A. (1988) The European Challenge 1992: The Benefits of a Single Market, Aldershot, UK: Wildwood House.
16. CECG (1993) Pharmaceuticals in the Single Market, Consumers in the European Community Group.
17. Chambers , G. and Belcher , P. (1994) 'The Consumption of Medicines in the European Union', in E. Mossialos , C. Ranos and B. Abel-Smith (eds) Cost Containment, Pricing and Financing of Pharmaceuticals in the European Community: The Policy-Makers' View, Athens: LSE Health and Pharmetrica.
18. Christiansen , T. (1997) 'Reconstructing European Space: From Territorial Politics to Multilevel Governance', in K.-E. Jorgensen (ed.) Reflective Approaches to European Governance, Basingstoke, UK: Macmillan.
19. COM (1993) 'Commission Communication to the Council and Parliament on the outlines of an industrial policy for the pharmaceutical sector in the European Community', COM (93) 718, 02.03.94.
20. COM (1998) 'Commission Communication on the Single Market in Pharmaceuticals', COM(98) 588 final, Brussels: Commission of the European Communities.
21. CPMP (1994) Annual report 1993-1994, Brussels: Committee for Proprietary Medicinal Products.
22. Deboyser , P. (1995) 'An Industrial Policy for the Pharmaceutical Industry', in N. Mattisen and E. Mossialos (eds) Healthcare Reforms and the Role of the Pharmaceutical Industry, Basel: Pharmaceutical Partners for Better Healthcare.
23. ECJ (1996) 'European Court of Justice. Judgement of 5 December 1996 in joint cases C-267/95 Merck v. Primecrown and C-268/95 Beecham v. Europharm, Luxembourg: European Court of Justice; 6285-6392.
24. EFPIA (2001) The Pharmaceutical Industry in Figures - Key Data (2001 Update), Brussels: European Federation of Pharmaceutical Industries and Associations (EFPIA).
25. EFPIA-EMEA (1999) 'EFPIA INFO DAY 2000 MINUS 2: Performance Indicators of the Centralised Procedure', 1999 (http://www.eudra.org/gendocs/PDFs/GENERAL/infodayen.pdf).
26. EMEA (1996) 'First General Report on the Activities of the European Agency for the Evaluation of Medicinal Products 1995, EMEA/MB/065/95.
27. EMEA FAQs 'The European Agency for the Evaluation of Medicinal Products: Frequently Asked Questions' (http://www.eudra.org/gendocs/PDFs/GENERAL/FAQs/FAQen.pdf).
28. Furniss , J. (1997) 'The Bangemann Round Table: A Beginning and Not an End', Eurohealth 3 (1): 27-28.
29. Garattini , S. and Bertele' , V. (2001) 'Adjusting Europe's Drug Regulation to Public Health needs', The Lancet 358: 64-67.
30. Greenwood , J. and Ronit , K. (1994) 'Interest Groups in the European Community: Newly Emerging Dynamics and Forms', West European Politics 17: 31-52.
31. Hancher , L. (1990) 'The European Pharmaceutical Market: Problems of Partial Harmonisation', European Law Review 15: 9-33.
32. Héritier , A. , Knill , C. and Mingers , S. (1996) Ringing the Changes in Europe: Regulatory Competition and the Transformation of the State - Britain, France, Germany, Berlin: Walter de Gruyter.
33. Hix , S. (1994) 'The Study of the European Community: The Challenge to Comparative Politics', West European Politics 17 (1): 1-30.
34. Hood , C. (1994) Explaining Economic Policy Reversals, Buckingham, UK: Open University Press.
35. Huttin , C. (1999) 'Drug Price Divergence in Europe: Regulatory Aspects', Health Affairs 18 (3), May/June: 245-249.
36. Kanavos , P. and Mossialos , E. (1999) 'Outstanding Regulatory Aspects in the European Pharmaceutical Market', Pharmacoeconomics 15 (6): 519-533.
37. Koberstein , W. (1993) 'EC: The Euro Revolution', Pharmaceutical Executive January: 28-30.
38. Kolko , G. (1963) The Triumph of Conservatism: A Reinterpretation of American History, 1900-1916, New York: Free Press.
39. Lowi , T. (1969) The End of Liberalism, New York: W.W. Norton.
40. McGowan , F. and Wallace , H. (1996) 'Towards a European Regulatory State', Journal of European Public Policy 3 (4): 560-576.
41. Majone , G. (ed.) (1996) Regulating Europe, London: Routledge.
42. Marks , G. , Hooghe , L. and Blank , K. (1996) 'European Integration from the 1980s: State-centric v. Multi-level Governance', Journal of Common Market Studies 1996; 34 (3): 343-378.
43. Matthews , D. and Wilson , C. (1998) 'Pharmaceutical Regulation in the Single European Market', Medicine and Law 17: 401-427.
44. Moravcsik , A. (1993) 'Preferences and Power in the European Community: A Liberal Intergovernmentalist Approach', Journal of Common Market Studies 31(4): 473-524.
45. Mossialos , E. and Abel-Smith , B. (1997) 'The Regulation of the European Pharmaceutical Industry', in S. Stavridis , E. Mossialos , R. Morgan and H. Machin (eds) New Challenges to the European Union: Policies and Policy-Making, Aldershot, UK: Dartmouth.
46. Mossialos , E. and Permanand , G. (2000) Public Health in the European Union: Making It Relevant, LSE Health Discussion Paper 17, London School of Economics and Political Science: LSE Health.
47. Orzack , L. (1996) 'Professionals, Consumers, and the European Medicines Agency: Policy-Making in the European Union', Current Research on Occupations and Professions 9: 9-29.
48. Permanand , G. (2002) 'Regulating under Constraint: The Case of EU Pharmaceutical Policy', PhD dissertation, London School of Economics and Political Science.
49. Sauer , F. (2000) 'New Drugs in the Global Economy: Risk Assessment and Risk Management in the European Union and Co-operation with the USA', speech delivered to the Graduate School of Public Health, University of Pittsburgh, 13 November 2000.
50. Shechter , Y. (1998) 'Interests, Strategies, and Institutions: Lobbying in the Pharmaceutical Industry of the European Union', PhD dissertation, London School of Economics and Political Science.
51. Stigler , G. (1971) 'The Theory of Economic Regulation', Bell Journal of Economics and Management Science 2 (1): 3-21.
52. Wilson , J. (1980) 'The Politics of Regulation', in James Q. Wilson (ed.) The Politics of Regulation, New York: Basic Books.